II. Indications
III. Mechanism
- See Alkylating Agent
- Antineoplastic nitrosourea
- Alkylating Agent that cross-links DNA during all Cell Cycle phases
- Carbamoylates Proteins, including DNA repair Proteins, resulting in further cytotoxic effects
IV. Medications
- Oral Lomustine: 5, 10, 40 and 100 mg capsules
- Dispensed as single doses
V. Dosing
- See other references for disease specific dosing protocols
- Typically taken every 6 weeks during treatment
VI. Pharmacokinetics
- Lipophilic
- Easily crosses the blood brain barrier
- Narrow therapeutic range
- Fatalities have occurred with overdosage (dispense one dose at a time)
VII. Adverse Effects
- Alopecia
- Severe Bone Marror Suppression
- Hepatotoxicity
- Impaired future fertility
- Nephrotoxicity
- Pulmonary Fibrosis
- Secondary Malignancy
VIII. Safety
- Avoid in Lactation
- Pregnancy Category D
- Avoid in Pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
IX. Resources
- Lomustine Capsule (DailyMed)
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis. This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing. Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04) |
Definition (NCI_NCI-GLOSS) | An anticancer drug that belongs to the family of drugs called alkylating agents. |
Definition (MSH) | An alkylating agent of value against both hematologic malignancies and solid tumors. |
Definition (CSP) | cytotoxic alkylating agent of the nitrosourea group used as an antineoplastic. |
Definition (PDQ) | A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis. This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing. Lomustine is lipophilic and crosses the blood-brain barrier. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43065&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43065&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C617" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D008130 |
SnomedCT | 387227009, 40999006 |
English | Lomustine, Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-, Chloroethylcyclo- hexylnitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea, lomustine, Chloroethylcyclo-hexylnitrosourea, chloroethylcyclohexylnitrosourea, Lomustinum, lomustine (medication), Lomustine [Chemical/Ingredient], cyclohexylchloroethylnitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, Lomustine (product), Lomustine (substance), Chloroethylcyclohexylnitrosourea, LOMUSTINE |
Swedish | Lomustin |
Czech | lomustin |
Finnish | Lomustiini |
Russian | LOMUSTIN, CCNU, ЛОМУСТИН |
Japanese | ロムスチン |
Polish | Lomustyna |
Spanish | lomustina (producto), lomustina (sustancia), lomustina, Lomustina |
French | Lomustine |
German | Lomustin |
Italian | Lomustina |
Portuguese | Lomustina |